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Background. Some patients are not prescribed atazanavir because of concern about possible jaundice. Atazana-
vir-associated hyperbilirubinemia correlates with UGT1A1 rs887829 genotype. We examined bilirubin-related dis-
continuation of atazanavir in participants from AIDS Clinical Trials Group Study A5257.
Methods. Discriminatory properties of UGT1A1 T/T genotype for predicting bilirubin-related atazanavir dis-
continuation through 96 weeks after antiretroviral initiation were estimated.
Results. Genetic analyses involved 1450 participants, including 481 who initiated randomized atazanavir/rito-
navir. Positive predictive values of rs887829 T/T for bilirubin-related discontinuation of atazanavir (with 95% con-
ﬁdence intervals [CIs]) were 20% (CI, 9%–36%) in Black, 60% (CI, 32%–84%) in White, and 29% (CI, 8%–58%) in
Hispanic participants; negative predictive values were 97% (CI, 93%–99%), 95% (CI, 90%–98%), and 97% (CI, 90%–
100%), respectively.
Conclusions. Bilirubin-related discontinuation of atazanavir was rare in participants not homozygous for
rs887829 T/T, regardless of race or ethnicity. We hypothesize that the higher rate of discontinuation among
White participants homozygous for rs887829 T/T may reﬂect differences in physical manifestations of jaundice
by race and ethnicity. Selective avoidance of atazanavir initiation among individuals with T/T genotypes would
markedly reduce the likelihood of bilirubin-related discontinuation of atazanavir while allowing atazanavir to be pre-
scribed to the majority of individuals. This genetic association will also affect atazanavir/cobicistat.
Keywords. atazanavir; HIV; pharmacogenomics; pharmacokinetics; UGT1A1.
The once-daily human immunodeﬁciency virus (HIV)-
1 protease inhibitor atazanavir with low-dose ritonavir
as a pharmacokinetic enhancer (atazanavir/r) is gener-
ally safe and effective as a ﬁrst-line regimen for HIV-1
infection [1–4]. Atazanavir increases plasma indirect
bilirubin concentrations by inhibiting uridine diphos-
phate glucuronosyltransferase (UGT) 1A1-mediated bi-
lirubin glucuronidation [5]. This provides a reliable
biomarker of very recent medication adherence [6–8].
Atazanavir-associated indirect hyperbilirubinemia
does not indicate hepatic injury [2, 9–11], but some pa-
tients discontinue atazanavir due to cosmetic jaundice
[3, 12, 13], and many are not prescribed atazanavir to
avoid this possibility. Better pretreatment prediction
of atazanavir intolerance due to hyperbilirubinemia
could reduce jaundice-related atazanavir discontinuations.
Polymorphisms in UGT1A1 are associated with in-
terindividual differences in plasma indirect bilirubin
concentrations in the general population (ie, Gilbert’s
syndrome). A promoter tandem TA repeat, UGT1A1*28
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(TA)7, is associated with reduced UGT1A1 transcription
compared with UGT1A1*1 (TA)6 [14, 15]. Among atazanavir
recipients, UGT1A1*28 has been strongly associated with un-
conjugated hyperbilirubinemia [16, 17], as has a C→T single-
nucleotide polymorphism (rs887829) in almost complete linkage
disequilibrium with UGT1A1*28 [18]. In a genome-wide study
involving individuals who had been randomized to atazanavir-
containing regimens in AIDS Clinical Trials Group (ACTG)
protocol A5202, rs887829 genotype, baseline indirect bilirubin,
and baseline hemoglobin were each independently associated
with peak on-treatment total bilirubin concentration [18].How-
ever, reported associations between UGT1A1 genotype and ata-
zanavir discontinuation have been inconsistent [17, 19].
In ACTG protocol A5257, participants were randomized to
receive atazanavir/r, darunavir/ritonavir (darunavir/r), or ralte-
gravir, all with concomitant tenofovir disoproxil fumarate
(TDF)/emtricitabine. The present study examined whether
UGT1A1 genotype, baseline indirect bilirubin, and/or baseline
hemoglobin were associated with bilirubin-related discontinua-
tion of atazanavir/r in A5257, and whether associations differed
by race or ethnic group. We also assessed whether tolerability of
regimens containing atazanavir/r compared with darunavir/r or
raltegravir differed by UGT1A1 genotype.
METHODS
Study Participants
Protocol A5257 was a phase III prospective randomized open-
label trial comparing 3 nonnucleoside reverse transcriptase in-
hibitor-sparing antiretroviral regimens for initial treatment of
HIV-1 infection. Primary results of A5257 were previously pub-
lished [20]. In brief, A5257 participants enrolled from 2009 to
2011 at research sites in the United States and Puerto Rico were
randomized to open-label atazanavir (300 mg) plus ritonavir
(100 mg), darunavir (800 mg) plus ritonavir (100 mg), or
raltegravir (400 mg), all with concomitant TDF/emtricitabine
(300 mg/200 mg). Study medications were once daily except
for raltegravir, which was twice daily. Study evaluations were
performed before entry, at entry, at weeks 4, 8, 16 and 24, 36,
and 48, and every 16 weeks thereafter until the last enrolled
subject was followed for 96 weeks. Bilirubin and hemoglobin
were assayed individually as per standard procedures at each
clinical research site. Participants with asymptomatic hyperbi-
lirubinemia were allowed to continue atazanavir/r if the site in-
vestigator felt that the hyperbilirubinemia was not clinically
relevant.
Identifying Genetic Polymorphisms
Consent for genetic analyses was obtained under ACTG proto-
col A5128 [21]. The Vanderbilt University Institutional Review
Board and the ACTG approved this use of DNA. Genotypes for
rs887829 (hereafter called UGT1A1 genotype) were available
from Illumina HumanCore Exome Chip data generated by
Vanderbilt Technologies for Advanced Genomics, and these ge-
notypes provided results for 523 486 polymorphisms with call
rates ≥99%. Laboratory personnel blinded to clinical data per-
formed genotyping. Genetic data management and association
analyses were performed with PLINK version 1.07 [22]. Sam-
ples that clustered to African American, European, or Hispanic
genetic ancestry are hereafter called Black, White, and Hispanic,
respectively. Clustering of samples was done by multidimen-
sional scaling (MDS) implemented in PLINK.
Statistical Analyses
The target population for this study was Black, White, or Hispan-
ic participants who initiated randomized treatment in A5257 and
had genotype data available. Primary endpoints for the analysis
were time to bilirubin-related discontinuation of atazanavir/r by
96 weeks. Attribution of reasons for discontinuation of random-
ized treatment, including details of toxicity or adverse events and
participant-initiated discontinuations that were due to low-grade
adverse events, was based on site report. Bilirubin-related events
were deﬁned a priori as those reported as being due to jaundice,
elevated bilirubin, or hyperpigmentation. Inconsistent or unclear
information was reconciled by site query.
Cumulative incidence of bilirubin-related discontinuation of
atazanavir/r was estimated using a competing risks framework
and compared across UGT1A1 genotypes using Gray’s test.
Cox proportional hazard models were used to estimate relative
hazards of bilirubin-related discontinuation of atazanavir/r by
UGT1A1 genotype with and without adjusting for baseline indi-
rect bilirubin and baseline hemoglobin. Mirroring the primary
A5257 analyses, the cumulative incidence of tolerability failure
over 96 weeks was estimated by UGT1A1 genotype with pairwise
differences compared between randomized atazanavir/r, daruna-
vir/r, and raltegravir via 97.5% conﬁdence intervals (CIs) [20].
Discriminatory properties (positive predictive value [PPV] and
negative predictive value [NPV]) of UGT1A1 T/T genotype for
predicting bilirubin-related atazanavir/r discontinuation through
96 weeks after antiretroviral initiation (binary outcome) were es-
timated with exact 95% CIs. All analyses were performed using
SAS 9.2 without adjusting for multiple comparisons.
All analyses were done separately by self-identiﬁed race or
ethnicity. To minimize potential errors due to race or ethnicity
misclassiﬁcation, sensitivity analyses were performed based on
inferred ancestry using genome-wide data with exclusion of




Among 605 participants randomized to the atazanavir/r-
containing arm in A5257, 600 initiated the regimen and had
2 • OFID • Vardhanabhuti et al
available treatment discontinuation data. Among these 600 par-
ticipants, 493 participants had genotype data available, 481 of
whom were self-identiﬁed as Black non-Hispanic, White non-
Hispanic, or Hispanic. Derivation of the study population is
shown in Figure 1. Baseline characteristics and genotype fre-
quencies of study participants from the atazanavir/r arm are
shown in Table 1. Among the 481 participants, median age
was 38 years, median body mass index was 25 kg/m2, and
23% were female, consistent with the full study population. Fre-
quency of UGT1A1 T/T genotype varied by race or ethnicity
(19% in Black, 8% in White, 16% in Hispanic participants). Ge-
notype data were unavailable on 107 participants because they
either did not consent to genetic testing or because genotyping
was unsuccessful.
Associations With Bilirubin-Related Atazanavir/r
Discontinuation
Among the 481 evaluable participants, 146 (30%) prematurely
discontinued atazanavir/r (29%, 30%, and 34% among Black,
White, and Hispanic participants, respectively). Among these
146 participants, most atazanavir/r discontinuations were not
bilirubin-related, regardless of race or ethnicity; discontinuation
was considered bilirubin-related in 37 (25%), including 13 (21%)
of 62 Black participants, 18 (33%) of 54White participants, and 6
(20%) of 30 Hispanic participants. Among all 481 participants,
there was an 8% likelihood of bilirubin-related discontinuation
of atazanavir/r (6%, 10%, and 7% among Black, White, and His-
panic participants, respectively). Other frequently reported
reasons of atazanavir/r discontinuation were nonadherence
(n = 35) and gastrointestinal toxicity (n = 21).
The UGT1A1 genotype was associated with time to bilirubin-
related discontinuation of atazanavir/r in Black (P = 3.0 × 10−4),
White (P = 1.8 × 10−11), and Hispanic (P = 2.3 × 10−3) partici-
pants (Figure 2). Participants with T/T genotype had higher
cumulative incidence of bilirubin-related atazanavir/r discon-
tinuation compared with non-TT genotypes regardless of race
or ethnicity by visual inspection; the magnitude of the effect
varied by race or ethnicity (P < .0001). In Cox proportional
hazards models stratiﬁed by race/ethnicity, and that included
baseline indirect bilirubin and baseline hemoglobin, only
UGT1A1 T/T genotype was independently associated with bilir-
ubin-related atazanavir/r discontinuation, with a hazard ratio
that ranged from 10 in Black participants to 24 in White partic-
ipants (Table 2).
Discriminative Properties of Bilirubin-Related Discontinuation
of Atazanavir
Positive and NPVs of UGT1A1 genotype and/or baseline
indirect bilirubin for bilirubin-related discontinuation of ataza-
navir/r by 96 weeks are presented in Table 3. Among partici-
pants with UGT1A1 T/T genotypes, the probabilities of
bilirubin-related discontinuation of atazanavir/r (ie, PPV)
were 20% in Blacks, 60% in Whites, and 29% in Hispanics.
Among participants with non-TT UGT1A1 genotypes, the
Table 1. Baseline Characteristics of Study Participants
Drug Discontinuation
Analyses (N = 481)
Race/ethnicity
















Median BMI in kg/m2 (IQR) 25 (23–29)
Median age in years (IQR) 38 (29–45)
Median baseline bilirubin mg/dL (IQR) 0.4 (0.2–0.6)a
Median baseline hemoglobin g/dL (IQR) 13.9 (12.4–14.9)a
Abbreviations: BMI, body mass index; IQR, interquartile range.
a Based on 438 participants with baseline covariates.
Figure 1. Derivation of the study population. Of 605 participants ran-
domized to the atazanavir/r arm in A5257, a total of 481 were included
in genetic association analyses for treatment discontinuation and 438 in
analyses with baseline covariates. Of participants randomized to the dar-
unavir/r and raltegravir arms, 491 and 478, respectively, were included in
analyses for treatment discontinuation. Abbreviations: ART, antiretroviral
therapy; SNP, single-nucleotide polymorphism.
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probability of not experiencing bilirubin-related discontinua-
tion of atazanavir/r (ie, NPV) ranged from 95% to 97%.
The PPV of baseline indirect bilirubin >0.4 mg/dL (threshold
based on the median value) for bilirubin-related discontinua-
tion of atazanavir/r by 96 weeks stratiﬁed by race or ethnicity
ranged from 13% to 18%, whereas the NPV ranged from 96%
to 98%. Considering the combination of UGT1A1 T/T genotype
and baseline indirect bilirubin >0.4 mg/dL, by race or ethnicity,
the PPV ranged from 23% to 75%, and the NPV ranged from
94% to 97%.
Comparisons Between Randomized Treatment Arms
In A5257, primary treatment arm comparisons for all-cause tol-
erability failure over 96 weeks showed atazanavir/r to be inferior
to both darunavir/r and raltegravir [20].We repeated these anal-
yses, within subgroups deﬁned by UGT1A1 genotype. Compar-
ing atazanavir/r and darunavir/r arms, among participants with
UGT1A1 C/C, the estimated difference in 96-week cumulative
incidence of all-cause tolerability failure was within the
prespeciﬁed A5257 equivalence boundary, and among partici-
pants with UGT1A1 C/T was close to this boundary. In contrast,
the estimated differences in 96-week cumulative incidence of
tolerability failure with 97.5% CIs demonstrated inferiority for
atazanavir/r compared with raltegravir regardless of UGT1A1
genotype (Figure 3).
Sensitivity Analyses
Sensitivity analyses were performed based on inferred ancestry
using genome-wide data. These analyses censored 28 partici-
pants who, by MDS plot, did not cluster into distinct subgroups.
Results and conclusions were unchanged in sensitivity analyses
after removal of outliers (data not shown).
DISCUSSION
The present study showed that, among 481 participants who ini-
tiated atazanavir/r in A5257, the likelihood of bilirubin-related
discontinuation of atazanavir/r was low among participants
Figure 2. Cumulative incidence of time to bilirubin-associated discontinuation of atazanavir/r stratiﬁed by UGT1A1 genotype. Lines estimate the cumu-
lative incidence of time to bilirubin-associated discontinuation of atazanavir, stratiﬁed by UGT1A1 rs887829 genotype and self-reported race or ethnicity. (A)
All participants; (B) Black participants; (C) White participants; (D) Hispanic participants. P values are given by Gray’s test for testing equality of cumulative
incidence functions. Solid lines represent rs887829 T/T, dashed lines represent rs887829 C/T, and dotted lines represent rs887829 C/C. Number of par-
ticipants in the risk set over time for each genotype are shown in each plot.
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with UGT1A1 non-T/T genotypes (ie, C/C or C/T) regardless of
race or ethnicity, and this was substantially higher among par-
ticipants with UGT1A1 T/T genotype regardless of race or eth-
nicity and was particularly high among White participants.
These ﬁndings indicate that avoidance of atazanavir prescribing
to individuals with UGT1A1 T/T genotypes would have reduced
by approximately one-half the likelihood of bilirubin-related dis-
continuation of atazanavir, regardless of race or ethnicity. This
approach would have still allowed atazanavir/r to be prescribed
to the large percentage of individuals (81% of Black participants,
92% of White participants, and 84% of Hispanic participants)
who are at low risk for bilirubin-related discontinuation.
We also examined the ability of baseline indirect bilirubin to
predict bilirubin-related discontinuation of atazanavir among
438 participants who initiated atazanavir/r and had available
baseline indirect bilirubin, regardless of genotype. Selective
avoidance of atazanavir/r in individuals with baseline indirect bi-
lirubin >0.4 mg/dL would have also reduced by approximately
one half the likelihood of bilirubin-related discontinuation of ata-
zanavir, regardless of race or ethnicity, but would have allowed
atazanavir/r to be prescribed to only 70% of Black participants,
55% of White participants, and 65% of Hispanic participants.
Finally, we examined the predictive utility of UGT1A1 geno-
type and baseline indirect bilirubin in combination. With
both UGT1A1 T/T genotype and baseline indirect bilirubin
>0.4 mg/dL, the likelihood of bilirubin-related discontinuation
of atazanavir/r was modestly higher compared with considering
baseline indirect bilirubin orUGT1A1 genotype alone. Prescrib-
ing atazanavir/r only to individuals who both lacked UGT1A1
T/T and had baseline indirect bilirubin ≤0.4 mg/dL would
have also reduced by approximately one half the likelihood of
bilirubin-related discontinuation of atazanavir, regardless of
race or ethnicity, but would have allowed atazanavir/r prescrib-
ing to only 62% of Black participants, 53% of White partici-
pants, and 57% of Hispanic participants.
Overall, the reductions in bilirubin-related discontinuation
were similar in all race and ethnic groups whether by screening
Table 2. Cox Proportional Hazard Model for Bilirubin-Associat-
ed Discontinuation of Atazanavir/r With UGT1A1 Genotype, Base-
line Indirect Bilirubin, and Baseline Hemoglobin
Estimate
(SE) HR [95% CI] P Value
Black
rs887829 T/T 2.32 (1.09) 10 [1.2, 85] .033
rs887829 C/T 0.94 (1.12) 2.6 [.3, 23] .40
Baseline indirect
bilirubin
0.83 (0.61) 2.3 [.7, 7.6] .17
Baseline hemoglobin 0.57 (0.56) 1.8 [.6, 5.4] .31
White
rs887829 T/T 3.16 (0.83) 24 [4.7, 119] 1.3 × 10−4
rs887829 C/T 1.02 (0.81) 2.8 [.6, 14] .21
Baseline indirect
bilirubin
1.05 (0.63) 2.9 [.8, 9.9] .09
Baseline hemoglobin −0.04 (0.52) [.3, 2.7] .93
Hispanic
rs887829 T/T 2.48 (1.15) 12 [1.3, 113] .031
rs887829 C/T −0.27 (1.43) 0.8 [.0, 13] .85
Baseline indirect
bilirubin
0.39 (0.91) 1.5 [.3, 8.8] .66
Baseline hemoglobin 1.62 (1.20) 5.1 [.5, 53] .17
Abbreviations: CI, confidence interval; HR, hazards ratio; SE, standard error.
Table 3. Positive and Negative Predictive Values of UGT1A1 rs887829 and Baseline Bilirubin for Bilirubin-Associated Drug
Discontinuation
Positive Predictive Valuea
[No. of Subjects Positive
Test] (95% CI)
Negative Predictive Valueb
[No. of Subjects Negative
Test] (95% CI)




Black 20% [40] (9%–36%) 97% [171] (93%–99%) 19.0%
White 60% [15] (32%–84%) 95% [168] (90%–98%) 8.2%
Hispanic 29% [14] (8%–58%) 97% [73] (90%–100%) 16.1%
Baseline bilirubin
Black 14% [59] (6%–25%) 96% [139] (92%–99%) 29.8%
White 18% [78] (10%–28%) 96% [94] (89%–99%) 45.3%
Hispanic 13% [24] (3%–32%) 98% [44] (88%–100%) 35.3%
UGT1A1 genotype and baseline bilirubin
Black 23% [22] (8%–45%) 98% [123] (94%–100%) 37.9%
White 75% [12] (43%–95%) 96% [91] (89%–99%) 47.1%
Hispanic 40% [5] (5%–85%) 97% [39] (87%–100%) 42.6%
Abbreviation: CI, confidence interval.
a Positive test: T/T genotype, or baseline bilirubin >0.4 mg/dL, or T/T genotype and baseline bilirubin >0.4 mg/dL.
b Negative test: non-T/T genotype, or baseline bilirubin ≤0.4 mg/dL, or non-T/T genotype and baseline bilirubin ≤0.4 mg/dL.
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for low risk based on baseline indirect bilirubin < 0.4, based on
non-TT UGT1A1 genotype, or considering both. However, con-
sidering just UGT1A1 genotype would allow atazanavir/r pre-
scribing a substantially greater percentage of participants. In
particular, among White participants, 92% could be prescribed
to atazanavir/r if screened using UGT1A1 genotype compared
with only 55% if screened using baseline indirect bilirubin.
With UGT1A1 T/T homozygosity, the likelihood of biliru-
bin-related atazanavir/r discontinuation was least in Black par-
ticipants, intermediate in Hispanic participants, and greatest in
White participants. We speculate that the extent to which jaun-
dice becomes visible differs depending on skin color and/or
ancestry.
Two previous studies that analyzed associations between
UGT1A1 genotype used all-cause discontinuation of atazana-
vir/r as the outcome of interest. In an observational study
involving 121 Swiss HIV Cohort Study participants (80% Cau-
casian) who had received atazanavir/r, carriage of UGT1A1 low
expresser alleles (*28/*28 or *28/*37) was associated with in-
creased risk of atazanavir/r discontinuation, with cumulative
rates of 63% among 18 participants carrying 2 alleles, 24%
among 48 participants carrying one allele, and 15% among 55
participants carrying no allele [19]. (The *28 and *37 low-
expresser alleles and the *36 high-expresser allele of UGT1A1
are all collectively identiﬁed an rs8175347.) In contrast, an
analysis involving 646 participants randomized to receive ataza-
navir/r in ACTG protocol A5202 found no signiﬁcant associa-
tion between low-expressor UGT1A1 genotype (primarily
UGT1A1*28) and increased likelihood of atazanavir/r discon-
tinuation among either White participants or Black partici-
pants, although there was an association among Hispanic
participants [17]. Our use of bilirubin-related atazanavir/r dis-
continuation as the outcome minimized confounding by other
factors unrelated to UGT1A1 genotype (eg, nonadherence) and
allowed genotype-phenotype associations to be more precisely
described. The somewhat different results of these 3 studies are
not due to genotyping differences (rs8175347 in prior studies,
rs887829 in the present study). These polymorphisms are in al-
most complete linkage disequilibrium (rs887829 C with both *1
and *36; rs887829 T with both *28 and *37), and the *36 and
Figure 3. Pairwise treatment differences in cumulative probability of all-cause tolerability failure by 96 weeks. (Top) Comparison between atazanavir/r
and darunavir/r arms. (Bottom) Comparison between atazanavir/r and raltegravir arms. Within each treatment comparison, the following are shown: Overall,
primary result from ACTG A5257; Overall (analysis), result restricted to participants with UGT1A1 genotype data; rs887829, results stratiﬁed by UGT1A1
genotype. Estimates of pairwise treatment differences are shown with 97.5% conﬁdence interval. The equivalence boundary for treatment comparison is
±10% and is represented by the shaded area. Abbreviations: ATV, atazanavir; DRV, darunavir; RAL, raltegravir.
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*37 alleles of rs8175347 are infrequent in the populations
studied.
There are several possible explanations for different results
between the present study and prior reports. The somewhat
higher atazanavir/r discontinuation rates in the Swiss HIV Co-
hort Study (including those not homozygous for the risk allele)
might have been inﬂuenced by discontinuations that were unre-
lated to bilirubin. The threshold to discontinue atazanavir/r for
jaundice might have been lower in that observational study than
in A5257, a prospective clinical trial. Likewise, in ACTG study
A5202, atazanavir/r discontinuations unrelated to bilirubin
might have obscured associations with UGT1A1 genotype. Con-
sistent with this ﬁnding, most atazanavir/r discontinuations in
the present study were attributed to causes other than bilirubin.
In the A5202 study, the alternative antiretroviral provided for
participants who developed jaundice (ie, lopinavir/r) may
have been considered less attractive than the alternatives provid-
ed by protocol A5257 (ie, darunavir/r and raltegravir), creating
a greater barrier to atazanavir/r discontinuation in A5202.
The HIV-1 protease inhibitors have relatively high genetic
barriers to viral drug resistance. For this reason, protease in-
hibitor-based regimens are sometimes prescribed to patients
who are at risk for nonadherence. With atazanavir/r, absence
of an increase in plasma bilirubin from baseline (regardless of
UGT1A1 genotype) strongly indicates that atazanavir/r was
not taken within the prior 24 hours. This biomarker of adher-
ence, often available from chemistry panels obtained at routine
clinic visits, could still be used among individuals with
UGT1A1 non-TT genotypes who are prescribed atazanavir/r.
Prior cost-effectiveness modeling indicated that UGT1A1 gen-
otyping to avoid atazanavir-related hyperbilirubinemia is cost
effective if comparator antiretroviral therapy regimens (eg,
atazanavir/r versus darunavir/r, each with TDF/emtricitabine)
have identical drug costs [23]. With UGT1A1 genotyping for
atazanavir, drug cost largely drives overall cost effectiveness. In
settings where differential drug costs encourage prescribing of
atazanavir/r-based regimens, patient care may beneﬁt from
UGT1A1 genotyping, with avoidance of atazanavir in the select
subset of patients at greatest risk for bilirubin-related discon-
tinuation. Many commercial laboratories in the United States
offer genotype testing for UGT1A1 (especially UGT1A1*28,
which is in almost complete linkage disequilibrium with
rs887829).
Among A5257 participants with UGT1A1 C/C genotype, the
cumulative incidence of all-cause tolerability failure by 96 weeks
with atazanavir/r versus darunavir/r was within the equivalence
boundary, and tolerability failure among participants with
UGT1A1 C/T genotype was almost within the equivalence
boundary. The tolerability beneﬁt of darunavir/r over atazana-
vir/r in A5257 was most pronounced among participants who
were homozygous for UGT1A1 T/T genotype. For atazanavir/r
versus raltegravir comparisons, the cumulative incidence of all-
cause tolerability failure by 96 weeks was inferior in atazanavir/r
even when considering the UGT1A1 genotype.
The present study had limitations. We focused on genotype
and clinical laboratory factors that were predetermined based
on previous studies [17, 19]. It is possible that additional genetic
or clinical factors could improve prediction of bilirubin-
associated discontinuation of atazanavir/r. The smaller sample
size for Hispanic participants may limit generalizability of
ﬁndings in this subgroup. We did not study atazanavir with
pharmacokinetic enhancement by cobicistat rather than ritona-
vir. However, atazanavir plasma concentration-time proﬁles
when prescribed with cobicistat are bioequivalent to those
with ritonavir [24]. Furthermore, in a double-blind clinical
trial that randomly assigned 692 patients to receive atazanavir
with either cobicistat or ritonavir, adverse events related to
bilirubin elevations (eg, hyperbilirubinemia, jaundice, and
scleral icterus) occurred in a similar percentage of patients in
the cobicistat and ritonavir arms (40.7% and 36.2%, respective-
ly), as did bilirubin-associated discontinuation of atazanavir
(3.5% and 3.2%, respectively) [25]. We therefore expect the as-
sociations between UGT1A1 genotype and bilirubin-associated
discontinuation of atazanavir/r reported in the present study to
also occur with atazanavir/cobicistat.
CONCLUSIONS
In summary, among participants randomized to receive
atazanavir/r with concomitant TDF/emtricitabine in A5257,
UGT1A1 T/T genotype predicted an increased likelihood of bi-
lirubin-associated discontinuation of atazanavir/r, regardless of
race or ethnicity. Selective avoidance of atazanavir initiation
among individuals with UGT1A1 T/T genotype would marked-
ly reduce the likelihood of bilirubin-related discontinuation of
atazanavir/r for hyperbilirubinemia. On April 8, 2015, the
Department of Health and Human Services’ Antiretroviral
Guidelines for Adults and Adolescents were updated to move
atazanavir from preferred to alternative status, explicitly based
on results of A5257 [4]. The present analyses suggest that,
among individuals known to have either rs887829 C/C or C/
T genotypes, atazanavir might still be considered for inclusion
in preferred regimens.
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